Cerebral venous sinus thrombosis and thrombocytopenia after COVID-19 vaccination – a report of two UK cases
No Thumbnail Available
Authors
Mehta, Puja R.
Apap Mangion, Sean
Benger, Matthew
Stanton, Biba R.
Czuprynska, Julia
Arya, Roopen
Sztriha, Laszlo K.
Check for full-text access
Issue Date
2021
Type
Article
Language
Keywords
Alternative Title
Abstract
Recent reports have highlighted rare, and sometimes fatal, cases of cerebral venous sinus thrombosis (CVST) and thrombocytopenia following the Vaxzevria vaccine. An underlying immunological mechanism similar to that of spontaneous heparin-induced thrombocytopenia (HIT) is suspected, with the identification of antibodies to platelet factor-4 (PF4), but without previous heparin exposure. This unusual mechanism has significant implications for the management approach used, which differs from usual treatment of CVST. We describe the cases of two young males, who developed severe thrombocytopenia and fatal CVST following the first dose of Vaxzevria. Both presented with a headache, with subsequent rapid neurological deterioration. One patient underwent PF4 antibody testing, which was positive. A rapid vaccination programme is essential in helping to control the COVID-19 pandemic. Hence, it is vital that such COVID-19 vaccine-associated events, which at this stage appear to be very rare, are viewed through this lens. However, some cases have proved fatal. It is critical that clinicians are alerted to the emergence of such events to facilitate appropriate management. Patients presenting with CVST features and thrombocytopenia post-vaccination should undergo PF4 antibody testing and be managed in a similar fashion to HIT, in particular avoiding heparin and platelet transfusions.
Description
Citation
Publisher
License
Journal
Brain, Behavior, and Immunity
Volume
95